News & Updates

Show Multimedia Only

Once-weekly semaglutide shows promise in alcohol use disorder

05 Mar 2025 by

Low-dose semaglutide may reduce alcohol craving and some drinking-related outcomes in patients with alcohol use disorder (AUD), a randomized clinical trial has shown.

Once-weekly semaglutide shows promise in alcohol use disorder

05 Mar 2025

GLP-1 receptor agonists reduce more fat than muscle mass

05 Mar 2025 by

Glucagon-like peptide-1 (GLP-1) receptor agonists likely induce weight loss by reducing more fat mass than muscle mass, a research team from the University of Hong Kong (HKU) has found.

GLP-1 receptor agonists reduce more fat than muscle mass

05 Mar 2025

No cardiovascular signal with anti-CGRP mAbs for migraine

05 Mar 2025

Migraine treatment with monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor does not appear to contribute to increased risk of cardiovascular disease (CVD) compared with onabotulinumtoxinA in adults, including those who are older and with disability, according to a retrospective cohort study.

No cardiovascular signal with anti-CGRP mAbs for migraine

05 Mar 2025

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025 by

The combination of nivolumab and ipilimumab (NIVO + IPI) significantly improves overall survival (OS) and objective response rate (ORR) compared with lenvatinib or sorafenib (LEN/SOR) in the first-line setting for patients with unresectable hepatocellular carcinoma (uHCC), based on the CheckMate 9DW expanded analyses presented at ASCO GI 2025.

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025

De-escalating ticagrelor monotherapy reduces bleeding in ACS

04 Mar 2025

De-escalation of dual antiplatelet therapy (DAPT) to ticagrelor monotherapy results in a decreased risk for major bleeding compared with standard DAPT among patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, reports a study.

De-escalating ticagrelor monotherapy reduces bleeding in ACS

04 Mar 2025

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

04 Mar 2025 by

Two-year treatment with brolucizumab 6 mg every 4 weeks demonstrates noninferiority in mean best-corrected visual acuity (BCVA), with superior anatomic outcomes, to aflibercept 2 mg every 4 weeks in patients with neovascular age-related macular degeneration (nAMD), as shown in the MERLIN study.

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

04 Mar 2025

Does SEP-1 increase sepsis mortality?

04 Mar 2025

Implementation of or compliance with the Severe Sepsis and Septic Shock Management Bundle (SEP-1) does not appear to contribute to mortality among patients with sepsis, as shown by the results of a systematic review.

Does SEP-1 increase sepsis mortality?

04 Mar 2025

Oestradiol patches bump up ADT armamentarium for prostate cancer

04 Mar 2025 by

Findings from a phase II trial demonstrate the potential of transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT) for men with metastatic (M1) prostate cancer who are on androgen receptor pathway inhibitors (ARPI).

Oestradiol patches bump up ADT armamentarium for prostate cancer

04 Mar 2025

Age does not influence ferric derisomaltose treatment outcomes

03 Mar 2025

In the treatment of patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, the use of ferric derisomaltose appears to result in similar outcomes across age groups, according to data from the open-label IRONMAN trial.

Age does not influence ferric derisomaltose treatment outcomes

03 Mar 2025

Singaporean youths grapple with depression, anxiety

03 Mar 2025 by

A significant portion of Singapore’s youth are experiencing ‘severe’ to ‘extremely severe’ levels of depression and anxiety, according to the National Youth Mental Health Study.

Singaporean youths grapple with depression, anxiety

03 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Once-weekly semaglutide shows promise in alcohol use disorder

Once-weekly semaglutide shows promise in alcohol use disorder

GLP-1 receptor agonists reduce more fat than muscle mass

GLP-1 receptor agonists reduce more fat than muscle mass

No cardiovascular signal with anti-CGRP mAbs for migraine

No cardiovascular signal with anti-CGRP mAbs for migraine

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

De-escalating ticagrelor monotherapy reduces bleeding in ACS

De-escalating ticagrelor monotherapy reduces bleeding in ACS

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

Does SEP-1 increase sepsis mortality?

Does SEP-1 increase sepsis mortality?

Oestradiol patches bump up ADT armamentarium for prostate cancer

Oestradiol patches bump up ADT armamentarium for prostate cancer

Age does not influence ferric derisomaltose treatment outcomes

Age does not influence ferric derisomaltose treatment outcomes

Singaporean youths grapple with depression, anxiety

Singaporean youths grapple with depression, anxiety